Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill aims to slow Parkinson's progression in early stages

NCT ID NCT06976268

Recruiting now Disease control Sponsor: Biohaven Therapeutics Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 07, 2026 · Updated 4 times

Summary

This study tests whether a daily pill called BHV-8000 can slow the worsening of motor skills in people recently diagnosed with Parkinson's disease. About 550 adults aged 40 to 85 with early Parkinson's will receive either BHV-8000 (10 mg or 20 mg) or a placebo for up to 48 weeks. The main goal is to see if the drug delays a meaningful decline in daily living abilities.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
BHV-8000 (a drug taken once daily as a pill)
What this could lead to
If it works, this could point toward a treatment that slows the progression of early Parkinson's disease, helping people stay independent longer.
What could go wrong
This is an early-to-mid-stage trial, so the drug may not prove effective or safe. Results from 550 people may not apply to everyone with Parkinson's.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease parkinsonian disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Site-005

    RECRUITING

    New York, New York, 10021, United States

  • Site-007

    RECRUITING

    Bellevue, Washington, 98007, United States

  • Site-015

    RECRUITING

    Farmington Hills, Michigan, 48334, United States

  • Site-017

    RECRUITING

    Boca Raton, Florida, 33486, United States

  • Site-027

    RECRUITING

    Chicago, Illinois, 60611, United States

  • Site-028

    RECRUITING

    New Haven, Connecticut, 06510, United States

  • Site-031

    RECRUITING

    Farmington, Connecticut, 06030, United States

  • Site-038

    RECRUITING

    Atlantis, Florida, 33462, United States

  • Site-041

    RECRUITING

    Los Angeles, California, 90033, United States

  • Site-043

    RECRUITING

    Round Rock, Texas, 78681, United States

  • Site-044

    RECRUITING

    Chesterfield, Missouri, 63005, United States

  • Site-049

    RECRUITING

    Birmingham, Alabama, 35294, United States

  • Site-051

    RECRUITING

    Maitland, Florida, 32751, United States

  • Site-071

    RECRUITING

    Boston, Massachusetts, 02114, United States

  • Site-074

    RECRUITING

    Newport News, Virginia, 23601, United States

  • Site-091

    RECRUITING

    Portland, Oregon, 97210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.